Retrospective Analysis of Adverse Drug Reactions Induced by Polatuzumab Vedotin
10.13748/j.cnki.issn1007-7693.20230183
- VernacularTitle:泊洛妥珠单抗不良反应的回顾性分析
- Author:
Ying LI
1
;
Tingting DAI
1
;
Dong WANG
2
Author Information
1. Tianjin Cancer Hospital Airport Hospital, Tianjin 300308, China
2. Tianjin Cancer Hospital Airport Hospital, Tianjin 300308, China；Tianjin Medical University Cancer Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin Clinical Research Center for Malignant Tumor, Tianjin 300060, China
- Publication Type:Journal Article
- Keywords:
polatuzumab vedotin；adverse drug reactions(ADR) ；retrospective analysis
- From:
Chinese Journal of Modern Applied Pharmacy
2024;41(8):1106-1110
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE :To study the general situation and characteristics of the adverse drug reactions(ADRs) associated with polatuzumab vedotin(combined with bendamustine and rituximab), so as to provide reference for clinical rational drug use.
METHODS
The clinical data of all patients who were hospitalized at Tianjin Cancer Hospital Airport Hospital and treated with polatuzumab vedotin during hospitalization from January 2021 to August 2022 were collected by searching Hospital Information System. The basic patient information, medication status, incidence of adverse reactions, etc, were collected and analyzed.
RESULTS
A total of 7 patients were enrolled in the analysis, which there were 4 males(57.1%) and 3 females(42.8%). The toxicity profile of polatuzumab vedotin consisted mainly of neutropenia and leukopenia. ADRs mainly occured within 3 months after administration, and it could be recovered after symptomatic treatment or observation, and there was no death due to ADRs.
CONCLUSION
During the rational use of polatuzumab vedotin in clinical practice, clinicians and pharmacists should reinforce the monitoring on its using to ensure the safe and effective of polatuzumab vedotin clinical application.
